CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
Latest Information Update: 31 Jan 2024
At a glance
- Drugs Rozanolixizumab (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Expanded access; Therapeutic Use
- Sponsors UCB Biopharma
- 23 Jan 2024 Status changed from recruiting to completed.
- 24 Aug 2021 New trial record